Robert C. Moen, MD, PhD
Dr. Moen has served as Copernicus‘ President and CEO since 1998, bringing his scientific, manufacturing, clinical, and regulatory expertise to drive the company’s nanoparticle gene therapy technologies forward.
He has been involved in over three dozen cellular and gene therapy clinical trials (mostly involving viral-based systems) as VP of Clinical and Regulatory Affairs of the Gene Therapy Unit at Baxter Healthcare; as VP of Clinical Development at Geneic Sciences; and as a co-founder and Director of Clinical and Regulatory Affairs (including QA) at Genetic Therapy, Inc. where he also served as Director of Cell Engineering, and also was in charge of the initial manufacturing and QC efforts. Genetic Therapy, Inc. was acquired by Sandoz (now Novartis) in 1995 for over $300MM. He also served at the National Institutes of Health (NIH) where he assisted in the development of the gene therapy program.
Prior to his service at the NIH, Dr. Moen was on the faculty of the University of Wisconsin. He is Board Certified in Pediatrics (Stanford University) and Allergy, Immunology (University of Wisconsin). He received his M.D. and Ph.D. in Biochemistry from the University of Washington – Seattle, and his B.A. in Biochemistry from Harvard.